臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 52800603 在线人数 : 617 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"shih j y"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 411-420 / 1137 (共114页)
<< < 37 38 39 40 41 42 43 44 45 46 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-03-11T08:29:30Z	Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs	Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T08:29:29Z	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort	Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T07:58:31Z	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma	Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T07:58:28Z	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study	Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T07:58:27Z	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations	Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y.
臺大學術典藏	2021-03-11T07:58:25Z	Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs	Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T07:58:24Z	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort	Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-08T06:51:51Z	Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression	Lin C.-C.; Huang Y.-K.; Cho C.-F.; Lin Y.-S.; Lo C.-C.; Kuo T.-T.; Tseng G.-C.; Cheng W.-C.; Chang W.-C.; Hsiao T.-H.; Liang-Chuan Lai; Shih J.-Y.; Liu Y.-H.; Clifford Chao K.S.; Hsu J.L.; Lee P.-C.; Sun X.; Hung M.-C.; Sher Y.-P.
臺大學術典藏	2021-02-23T08:26:39Z	Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response	Gow C.-H.;Chien C.-R.;Chang Y.-L.;Chiu Y.-H.;Sung-Hsin Kuo;Shih J.-Y.;Chang Y.-C.;Yu C.-J.;Yang C.-H.;Yang P.-C.; Gow C.-H.; Chien C.-R.; Chang Y.-L.; Chiu Y.-H.; SUNG-HSIN KUO; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang C.-H.; Yang P.-C.
臺大學術典藏	2021-02-23T08:26:37Z	Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial	Hsu C.; SUNG-HSIN KUO; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H.

显示项目 411-420 / 1137 (共114页)
<< < 37 38 39 40 41 42 43 44 45 46 > >>
每页显示[10|25|50]项目